AI Engines For more Details: Perplexity Kagi Labs You
UV Protection: Dioxybenzone helps to absorb and filter UV radiation, particularly in the UVA range. This protects the skin from the harmful effects of excessive sun exposure, including sunburn, premature aging, and an increased risk of skin cancer.
Skin Sensitivity: Some individuals may be sensitive or allergic to dioxybenzone, leading to skin irritation or allergic reactions. In such cases, alternative sunscreen ingredients may be recommended.
Environmental Concerns: There is growing concern about the environmental impact of certain sunscreen ingredients, including dioxybenzone. Studies have suggested that these compounds can accumulate in water bodies, potentially harming marine ecosystems, particularly coral reefs. Some regions have implemented regulations or bans on the use of certain sunscreen ingredients, including dioxybenzone, in an effort to protect marine environments.
Regulatory Considerations: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), closely monitor the safety and efficacy of sunscreen ingredients, including dioxybenzone. They establish guidelines for their use in consumer products to ensure their safety and effectiveness.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.1 | 0.6 | 4.17 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.7 | 1.4 | 0.21 |
| Allergies | 3.7 | 3.1 | 0.19 |
| Allergy to milk products | 2.3 | 1.6 | 0.44 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 5.3 | 3.9 | 0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.7 | 1.5 | 0.8 |
| Ankylosing spondylitis | 3.1 | 1.2 | 1.58 |
| Anorexia Nervosa | 1 | 1.6 | -0.6 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
| Asthma | 3.1 | 2 | 0.55 |
| Atherosclerosis | 2.2 | 0.5 | 3.4 |
| Atrial fibrillation | 2.7 | 2.2 | 0.23 |
| Autism | 5.6 | 6 | -0.07 |
| Autoimmune Disease | 0.9 | 0.3 | 2 |
| Barrett esophagus cancer | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 2.2 | 1.2 | 0.83 |
| Brain Trauma | 0.6 | 0.9 | -0.5 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 0.3 | 2 |
| Carcinoma | 3.4 | 1.9 | 0.79 |
| Celiac Disease | 1.6 | 2.9 | -0.81 |
| Cerebral Palsy | 1.3 | 0.6 | 1.17 |
| Chronic Fatigue Syndrome | 4.6 | 3 | 0.53 |
| Chronic Kidney Disease | 2.5 | 1.9 | 0.32 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.2 | 0.17 |
| Chronic Urticaria (Hives) | 1.5 | 0.8 | 0.88 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 0.3 | 4.33 |
| Cognitive Function | 1.6 | 0.6 | 1.67 |
| Colorectal Cancer | 4.6 | 1.7 | 1.71 |
| Constipation | 1.5 | 1.5 | |
| Coronary artery disease | 2.1 | 1.7 | 0.24 |
| COVID-19 | 6.2 | 5.6 | 0.11 |
| Crohn's Disease | 5.7 | 4.3 | 0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.2 | 0.7 | 0.71 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.1 | 0.6 | 2.5 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 7.1 | 6.1 | 0.16 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 1.2 | 0.6 | 1 |
| Endometriosis | 2.5 | 2 | 0.25 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.9 | 2.2 | 0.32 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 1.2 | 1.7 | -0.42 |
| Functional constipation / chronic idiopathic constipation | 4.1 | 2.1 | 0.95 |
| gallstone disease (gsd) | 2.4 | 1 | 1.4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0.3 | 1.67 |
| Generalized anxiety disorder | 2.8 | 1.3 | 1.15 |
| Gout | 1.3 | 0.7 | 0.86 |
| Graves' disease | 1.9 | 1.7 | 0.12 |
| Gulf War Syndrome | 0.3 | 1.5 | -4 |
| Halitosis | 0.9 | 0.9 | |
| Hashimoto's thyroiditis | 2.1 | 1.6 | 0.31 |
| Heart Failure | 2.6 | 1.3 | 1 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.6 | 0.6 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.6 | 0.5 |
| hyperglycemia | 2.3 | 2 | 0.15 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 3.7 | 2.5 | 0.48 |
| Hypothyroidism | 0.4 | 0.9 | -1.25 |
| Hypoxia | 2.6 | 0.3 | 7.67 |
| IgA nephropathy (IgAN) | 1.6 | 2.3 | -0.44 |
| Inflammatory Bowel Disease | 5.2 | 6 | -0.15 |
| Insomnia | 0.9 | 2.5 | -1.78 |
| Intelligence | 1.6 | 0.1 | 15 |
| Intracranial aneurysms | 1.3 | 0.6 | 1.17 |
| Irritable Bowel Syndrome | 4.6 | 4.5 | 0.02 |
| ischemic stroke | 2.2 | 1.2 | 0.83 |
| Liver Cirrhosis | 5.6 | 4.2 | 0.33 |
| Long COVID | 4.9 | 4.7 | 0.04 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 1.1 | 0.9 | 0.22 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.7 | 0.9 | -0.29 |
| ME/CFS with IBS | 1.2 | -1.2 | |
| ME/CFS without IBS | 0.9 | 0.6 | 0.5 |
| Menopause | 0.7 | 0.4 | 0.75 |
| Metabolic Syndrome | 5.4 | 4.5 | 0.2 |
| Mood Disorders | 7.6 | 5.8 | 0.31 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.7 | |
| Multiple Sclerosis | 4.1 | 2.2 | 0.86 |
| Multiple system atrophy (MSA) | 1 | 0.6 | 0.67 |
| myasthenia gravis | 0.6 | 0.6 | |
| neuropathic pain | 0.3 | 1.5 | -4 |
| Neuropathy (all types) | 0.7 | 1.1 | -0.57 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 3.2 | 0.13 |
| NonCeliac Gluten Sensitivity | 1.8 | 0.6 | 2 |
| Obesity | 6.4 | 5.1 | 0.25 |
| obsessive-compulsive disorder | 4.4 | 2.2 | 1 |
| Osteoarthritis | 1.4 | 1.3 | 0.08 |
| Osteoporosis | 1.8 | 0.9 | 1 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 6.3 | 3.5 | 0.8 |
| Polycystic ovary syndrome | 3.6 | 2.5 | 0.44 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 0.3 | 1 | -2.33 |
| Primary sclerosing cholangitis | 1.8 | 1.1 | 0.64 |
| Psoriasis | 2.1 | 2 | 0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.7 | 2.5 | 0.88 |
| Rosacea | 0.7 | 0.7 | |
| Schizophrenia | 5.3 | 2.6 | 1.04 |
| scoliosis | 0.9 | 0.6 | 0.5 |
| Sjögren syndrome | 2.2 | 1.9 | 0.16 |
| Sleep Apnea | 1.5 | 1.2 | 0.25 |
| Slow gastric motility / Gastroparesis | 1.4 | 0.3 | 3.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
| Stress / posttraumatic stress disorder | 2.3 | 2.7 | -0.17 |
| Systemic Lupus Erythematosus | 3.3 | 1.2 | 1.75 |
| Tic Disorder | 0.6 | 0.6 | 0 |
| Tourette syndrome | 0.4 | 0.3 | 0.33 |
| Type 1 Diabetes | 3.4 | 1.3 | 1.62 |
| Type 2 Diabetes | 5.4 | 4.5 | 0.2 |
| Ulcerative colitis | 3 | 4.5 | -0.5 |
| Unhealthy Ageing | 2.1 | 2 | 0.05 |
| Vitiligo | 1.8 | 1.7 | 0.06 |
